Keros Therapeutics (KROS) Other Operating Expenses (2019 - 2020)
Keros Therapeutics' (KROS) quarterly Other Operating Expenses came in at -$1.5 million in Q1 2020, down 146.69% YoY from $3.2 million in Q2 2019, and down 1810.26% on a QoQ basis from -$78000.0 in Q4 2019.
Keros Therapeutics (KROS) Other Operating Expenses (2019 - 2020) Analysis & Trends
Keros Therapeutics (KROS) has 2 years of Other Operating Expenses data on file, last reported at -$1.5 million in Q1 2020.
- Quarterly Other Operating Expenses fell 146.69% year-over-year to -$1.5 million in Q1 2020, while the trailing twelve-month figure through Dec 2020 was -$1.5 million (up 41.89% YoY) and the FY2020 annual result came in at -$1.5 million, up 41.89% from the prior year.
- Other Operating Expenses fell to -$1.5 million in Q1 2020, from -$78000.0 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of -$78000.0 in Q4 2019 to a low of -$1.5 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -1.49 Mn |
| Dec 31, 2019 | -78,000.00 |
| Sep 30, 2019 | -1.24 Mn |
| Jun 30, 2019 | -647,000.00 |
| Mar 31, 2019 | -604,000.00 |